Switch to:
Also traded in: Argentina, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
MRK's Cash to Debt is ranked lower than
67% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. MRK: N/A )
Ranked among companies with meaningful Cash to Debt only.
MRK' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.70 Max: 2.45
Current: N/A
0.32
2.45
Equity to Asset 0.45
MRK's Equity to Asset is ranked lower than
74% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. MRK: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
MRK' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.44 Max: 0.52
Current: 0.45
0.34
0.52
Interest Coverage 13.78
MRK's Interest Coverage is ranked lower than
77% of the 474 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.03 vs. MRK: 13.78 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.14  Med: 9.83 Max: 20.13
Current: 13.78
4.14
20.13
F-Score: 6
Z-Score: 2.70
M-Score: -2.58
WACC vs ROIC
6.83%
12.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.54
MRK's Operating margin (%) is ranked higher than
73% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.51 vs. MRK: 17.54 )
Ranked among companies with meaningful Operating margin (%) only.
MRK' s Operating margin (%) Range Over the Past 10 Years
Min: 6.43  Med: 16.45 Max: 25.15
Current: 17.54
6.43
25.15
Net-margin (%) 11.25
MRK's Net-margin (%) is ranked higher than
92% of the 684 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.44 vs. MRK: 11.25 )
Ranked among companies with meaningful Net-margin (%) only.
MRK' s Net-margin (%) Range Over the Past 10 Years
Min: 1.87  Med: 16.57 Max: 47.03
Current: 11.25
1.87
47.03
ROE (%) 11.41
MRK's ROE (%) is ranked higher than
87% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.23 vs. MRK: 11.41 )
Ranked among companies with meaningful ROE (%) only.
MRK' s ROE (%) Range Over the Past 10 Years
Min: 1.51  Med: 21.28 Max: 42.27
Current: 11.41
1.51
42.27
ROA (%) 5.20
MRK's ROA (%) is ranked higher than
78% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. MRK: 5.20 )
Ranked among companies with meaningful ROA (%) only.
MRK' s ROA (%) Range Over the Past 10 Years
Min: 0.79  Med: 8.49 Max: 16.34
Current: 5.2
0.79
16.34
ROC (Joel Greenblatt) (%) 54.69
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.81 vs. MRK: 54.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MRK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.88  Med: 43.79 Max: 104.88
Current: 54.69
10.88
104.88
Revenue Growth (3Y)(%) -2.40
MRK's Revenue Growth (3Y)(%) is ranked lower than
76% of the 581 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. MRK: -2.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.5  Med: 2.90 Max: 21.4
Current: -2.4
-16.5
21.4
EBITDA Growth (3Y)(%) 19.10
MRK's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. MRK: 19.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.6  Med: 0.90 Max: 44.7
Current: 19.1
-17.6
44.7
EPS Growth (3Y)(%) 26.30
MRK's EPS Growth (3Y)(%) is ranked higher than
78% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. MRK: 26.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.1  Med: 3.60 Max: 74.8
Current: 26.3
-43.1
74.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MRK Guru Trades in Q1 2015

Jim Simons 1,194,169 sh (+107.46%)
PRIMECAP Management 1,385,000 sh (+97.86%)
Paul Tudor Jones 97,093 sh (+82.93%)
RS Investment Management 898,325 sh (+33.15%)
Vanguard Health Care Fund 40,096,948 sh (+12.04%)
Mario Gabelli 160,943 sh (+11.45%)
James Barrow 24,464,116 sh (+7.03%)
Ken Fisher 6,679,499 sh (+0.59%)
T Rowe Price Equity Income Fund 6,625,700 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Richard Snow 5,375 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Ruane Cunniff 4,784 sh (unchged)
Ray Dalio Sold Out
Manning & Napier Advisors, Inc 398,354 sh (-0.22%)
Signature Select Canadian Fund 161,300 sh (-1.29%)
Jeff Auxier 145,334 sh (-1.36%)
Kahn Brothers 1,029,815 sh (-2.18%)
Mairs and Power 105,158 sh (-2.35%)
Charles Brandes 2,221,791 sh (-3.69%)
NWQ Managers 76,286 sh (-9.00%)
Tom Russo 3,836 sh (-11.53%)
Murray Stahl 41,051 sh (-12.29%)
Pioneer Investments 2,753,869 sh (-13.99%)
Dodge & Cox 25,448,977 sh (-24.30%)
Jeremy Grantham 8,922 sh (-31.49%)
Joel Greenblatt 676,758 sh (-35.28%)
Jeff Auxier 40,324 sh (-72.63%)
Steven Cohen 77,800 sh (-75.03%)
» More
Q2 2015

MRK Guru Trades in Q2 2015

Kyle Bass 35,404 sh (New)
Ray Dalio 17,141 sh (New)
David Dreman 11,463 sh (New)
Manning & Napier Advisors, Inc 6,347,239 sh (+1493.37%)
Jim Simons 1,921,734 sh (+60.93%)
PRIMECAP Management 2,042,000 sh (+47.44%)
Charles Brandes 2,817,473 sh (+26.81%)
Pioneer Investments 3,279,231 sh (+19.08%)
Vanguard Health Care Fund 45,748,498 sh (+14.09%)
James Barrow 25,641,122 sh (+4.81%)
Ken Fisher 6,836,547 sh (+2.35%)
Murray Stahl 41,151 sh (+0.24%)
Richard Snow 5,375 sh (unchged)
T Rowe Price Equity Income Fund 6,625,700 sh (unchged)
Tom Russo 3,836 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Ruane Cunniff 4,784 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Jeff Auxier 145,134 sh (-0.14%)
Kahn Brothers 1,016,613 sh (-1.28%)
Mairs and Power 102,874 sh (-2.17%)
Dodge & Cox 24,680,781 sh (-3.02%)
NWQ Managers 73,790 sh (-3.27%)
Mario Gabelli 148,540 sh (-7.71%)
RS Investment Management 747,565 sh (-16.78%)
RS Investment Management 747,565 sh (-16.78%)
Jeremy Grantham 6,500 sh (-27.15%)
Paul Tudor Jones 16,900 sh (-82.59%)
» More
Q3 2015

MRK Guru Trades in Q3 2015

Joel Greenblatt 5,844 sh (New)
Richard Snow 860,145 sh (+15902.70%)
Ray Dalio 251,746 sh (+1368.68%)
Paul Tudor Jones 44,663 sh (+164.28%)
PRIMECAP Management 2,645,000 sh (+29.53%)
Vanguard Health Care Fund 49,743,388 sh (+8.73%)
Murray Stahl 43,271 sh (+5.15%)
Pioneer Investments 3,427,061 sh (+4.51%)
Ruane Cunniff 4,994 sh (+4.39%)
Mairs and Power 104,124 sh (+1.22%)
Manning & Napier Advisors, Inc 6,347,239 sh (unchged)
Prem Watsa 12,000 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Kyle Bass Sold Out
RS Investment Management Sold Out
David Dreman Sold Out
Tom Russo Sold Out
Dodge & Cox 24,585,258 sh (-0.39%)
T Rowe Price Equity Income Fund 6,571,200 sh (-0.82%)
Charles Brandes 2,791,984 sh (-0.90%)
Kahn Brothers 1,006,208 sh (-1.02%)
Ken Fisher 6,761,706 sh (-1.09%)
James Barrow 25,179,076 sh (-1.80%)
Jeff Auxier 141,489 sh (-2.51%)
Manning & Napier Advisors, Inc 6,178,367 sh (-2.66%)
Mario Gabelli 142,715 sh (-3.92%)
Signature Select Canadian Fund 154,400 sh (-4.28%)
NWQ Managers 69,835 sh (-5.36%)
Jim Simons 1,461,734 sh (-23.94%)
Jeremy Grantham 4,200 sh (-35.38%)
» More
Q4 2015

MRK Guru Trades in Q4 2015

James Barrow 26,655,176 sh (+5.86%)
Vanguard Health Care Fund 50,476,700 sh (+1.47%)
Ken Fisher 6,822,070 sh (+0.89%)
Mario Gabelli 139,615 sh (-2.17%)
T Rowe Price Equity Income Fund 5,610,000 sh (-14.63%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Merck & Co Inc

Bill Nygren Comments on Merck - Apr 10, 2014

We eliminated our position in Merck (NYSE:MRK) as the shares appreciated to our estimate of fair value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Merck & Co Inc

5 Guru Picks in Volatile Biotech Industry Johnson & Johnson and Merck each have the backing of more than 25 gurus
Biotech and pharmaceutical stocks made some of the biggest headlines this year, as 2015 saw massive waves of M&A activity, including the Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) merger, the second-largest deal of all time valued at $160 billion. Other companies found themselves in the spotlight for less than desirable reasons, such as Valeant Pharmaceuticals (NYSE:VRX), whose stock has tanked in the past several months. Read more...
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? The question that needs to be asked about AbbVie's demise is: What caused the earnings decline in the last five years after it went public?
Merck & Co. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are two very different companies and face very different situations when it comes to earnings and growth, not to mention one is significantly older than the other. From 2009 to 2010, Merck's earnings fell by 14 times what they previously were but have made a comeback and have leveled out while AbbVie has only been public since 2013 and in its short history as a public has seen its earnings plunge by 20.31% annually. Merck's earnings have stayed consistent since its earnings recovered from 26 cents in December 2010 to $3.74 currently. Read more...
Vanguard Adds to Four of Its Largest Stakes
It isn’t surprising that nearly 95% of Vanguard Health Care Fund (Trades, Portfolio)’s holdings are related to health care, drug manufacturing and medical technology. But there has been some jockeying for position within the Fund’s portfolio in the early months of 2015. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 13.20
MRK's P/E(ttm) is ranked higher than
86% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.86 vs. MRK: 13.20 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.67  Med: 17.41 Max: 139.89
Current: 13.2
6.67
139.89
Forward P/E 13.21
MRK's Forward P/E is ranked higher than
100% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.50 vs. MRK: 13.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 13.20
MRK's PE(NRI) is ranked higher than
85% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.45 vs. MRK: 13.20 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s PE(NRI) Range Over the Past 10 Years
Min: 6.65  Med: 17.33 Max: 133.39
Current: 13.2
6.65
133.39
P/B 3.04
MRK's P/B is ranked lower than
56% of the 928 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.54 vs. MRK: 3.04 )
Ranked among companies with meaningful P/B only.
MRK' s P/B Range Over the Past 10 Years
Min: 1.72  Med: 3.22 Max: 7.25
Current: 3.04
1.72
7.25
P/S 3.55
MRK's P/S is ranked higher than
100% of the 929 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.60 vs. MRK: 3.55 )
Ranked among companies with meaningful P/S only.
MRK' s P/S Range Over the Past 10 Years
Min: 2.69  Med: 4.35 Max: 7.36
Current: 3.55
2.69
7.36
PFCF 29.57
MRK's PFCF is ranked higher than
56% of the 485 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.85 vs. MRK: 29.57 )
Ranked among companies with meaningful PFCF only.
MRK' s PFCF Range Over the Past 10 Years
Min: 7.87  Med: 15.90 Max: 86.81
Current: 29.57
7.87
86.81
POCF 19.91
MRK's POCF is ranked higher than
59% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.68 vs. MRK: 19.91 )
Ranked among companies with meaningful POCF only.
MRK' s POCF Range Over the Past 10 Years
Min: 6.68  Med: 13.18 Max: 35.75
Current: 19.91
6.68
35.75
EV-to-EBIT 30.00
MRK's EV-to-EBIT is ranked lower than
72% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.42 vs. MRK: 30.00 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 17.70 Max: 43.7
Current: 30
5.9
43.7
EV-to-EBITDA 15.41
MRK's EV-to-EBITDA is ranked higher than
52% of the 852 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. MRK: 15.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.2  Med: 11.40 Max: 20.3
Current: 15.41
5.2
20.3
PEG 3.30
MRK's PEG is ranked lower than
60% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. MRK: 3.30 )
Ranked among companies with meaningful PEG only.
MRK' s PEG Range Over the Past 10 Years
Min: 0.61  Med: 2.50 Max: 21.54
Current: 3.3
0.61
21.54
Shiller P/E 18.96
MRK's Shiller P/E is ranked higher than
83% of the 166 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.90 vs. MRK: 18.96 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s Shiller P/E Range Over the Past 10 Years
Min: 7.55  Med: 14.65 Max: 24.67
Current: 18.96
7.55
24.67
Current Ratio 1.62
MRK's Current Ratio is ranked lower than
65% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. MRK: 1.62 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.59 Max: 3.7
Current: 1.62
1.07
3.7
Quick Ratio 1.33
MRK's Quick Ratio is ranked lower than
60% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. MRK: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.24 Max: 3.44
Current: 1.33
0.8
3.44
Days Inventory 111.44
MRK's Days Inventory is ranked lower than
59% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.42 vs. MRK: 111.44 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 104.23  Med: 130.49 Max: 205.16
Current: 111.44
104.23
205.16
Days Sales Outstanding 59.27
MRK's Days Sales Outstanding is ranked higher than
64% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.67 vs. MRK: 59.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 57.78 Max: 87.87
Current: 59.27
44.5
87.87
Days Payable 49.44
MRK's Days Payable is ranked lower than
69% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. MRK: 49.44 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 30.2  Med: 42.08 Max: 90.81
Current: 49.44
30.2
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.67
MRK's Dividend Yield is ranked higher than
84% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.43 vs. MRK: 3.67 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s Dividend Yield Range Over the Past 10 Years
Min: 2.51  Med: 3.99 Max: 6.68
Current: 3.67
2.51
6.68
Dividend Payout 0.48
MRK's Dividend Payout is ranked higher than
65% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. MRK: 0.48 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s Dividend Payout Range Over the Past 10 Years
Min: 0.16  Med: 0.50 Max: 4.22
Current: 0.48
0.16
4.22
Dividend Growth (3y) 4.30
MRK's Dividend Growth (3y) is ranked lower than
56% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. MRK: 4.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MRK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.20 Max: 14.8
Current: 4.3
0
14.8
Forward Dividend Yield 3.73
MRK's Forward Dividend Yield is ranked higher than
84% of the 614 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. MRK: 3.73 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.38
MRK's Yield on cost (5-Year) is ranked higher than
81% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.79 vs. MRK: 4.38 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3  Med: 4.76 Max: 7.97
Current: 4.38
3
7.97
3-Year Average Share Buyback Ratio 1.80
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. MRK: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.10 Max: 1.8
Current: 1.8
-13
1.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.82
MRK's Price/Tangible Book is ranked lower than
97% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. MRK: 33.82 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.19  Med: 12.04 Max: 3735
Current: 33.82
3.19
3735
Price/Projected FCF 1.17
MRK's Price/Projected FCF is ranked higher than
84% of the 523 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. MRK: 1.17 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.23 Max: 3.04
Current: 1.17
0.75
3.04
Price/DCF (Earnings Based) 4.32
MRK's Price/DCF (Earnings Based) is ranked lower than
87% of the 124 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. MRK: 4.32 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.11
MRK's Price/Median PS Value is ranked higher than
54% of the 899 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. MRK: 1.11 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.66  Med: 1.23 Max: 2.03
Current: 1.11
0.66
2.03
Price/Peter Lynch Fair Value 0.99
MRK's Price/Peter Lynch Fair Value is ranked higher than
71% of the 244 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.72 vs. MRK: 0.99 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.64  Med: 1.63 Max: 11.48
Current: 0.99
0.64
11.48
Price/Graham Number 4.46
MRK's Price/Graham Number is ranked lower than
82% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.21 vs. MRK: 4.46 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.08  Med: 3.43 Max: 35.91
Current: 4.46
1.08
35.91
Earnings Yield (Greenblatt) (%) 3.30
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 720 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. MRK: 3.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 5.60 Max: 16.8
Current: 3.3
2.3
16.8
Forward Rate of Return (Yacktman) (%) 8.18
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
75% of the 318 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.62 vs. MRK: 8.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.7  Med: 6.40 Max: 20.4
Current: 8.18
-5.7
20.4

More Statistics

Revenue(Mil) $39498
EPS $ 1.56
Beta0.75
Short Percentage of Float1.06%
52-Week Range $45.69 - 61.70
Shares Outstanding(Mil)2793.54

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 40,326 40,295 41,091
EPS($) 3.73 3.78 3.76
EPS without NRI($) 3.73 3.78 3.76

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:MRK.Argentina, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Richard Snow Makes Huge Increases in Big-Name Stocks Jan 08 2016 
5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
Kahn Brothers' Largest Sales During 3rd Quarter Dec 22 2015 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Richard Snow Invests in Familiar Names in 3rd Quarter Nov 13 2015 
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? Nov 12 2015 
Pfizer to Create a New Pharmaceutical Colossus Nov 05 2015 
Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Nov 02 2015 
Charles Brandes' Most Weighted Trades in Q2 2015 Sep 30 2015 

More From Other Websites
ImmunoGen/Merck Collaborate for Ovarian Cancer Study Feb 05 2016
Merck & Co., Inc. Earnings Analysis: 2015 By the Numbers Feb 05 2016
FDA staff supports Celltrion's biosimilar Remicade Feb 05 2016
String of Q4 Earnings Beat Fails to Revive Pharma ETFs Feb 05 2016
FDA reviewers support Celltrion's biosimilar Remicade Feb 05 2016
It’s Time to Buy This Biotech Gem Feb 04 2016
Here's why ImmunoGen's CEO is psyched for combo tests with Keytruda Feb 04 2016
8:02 am Merck: FDA approves a sNDA for single-dose EMEND for injection in combination with other... Feb 04 2016
FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination... Feb 04 2016
Emerging Situations, Growth Study - Analyst Notes on Apple, Merck & Co, Wal Mart Stores and Home... Feb 04 2016
What Were the Overall Trends in Large-Cap Mutual Funds Last Year? Feb 04 2016
Merck Stock Slides As Q4 Revenue, Guidance Miss Expectations Feb 03 2016
Merck and Chipotle are big market movers Feb 03 2016
Edited Transcript of MRK earnings conference call or presentation 3-Feb-16 1:00pm GMT Feb 03 2016
[$$] Merck Revenue and Profit Fall Feb 03 2016
Merck Drops On Light Q4 Sales, Full-Year Guidance Feb 03 2016
Merck: A Leg Up In The Cancer Drug Race Feb 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK